



# The Pediatric Praziquantel Consortium

Its history and journey to success

Benjamin Dälken  
Senior Director, Global Program Lead  
Immunology & Global Health, Merck  
& Program Lead for the Pediatric  
Praziquantel Program  
Dec 9, 2021

# Background: A neglected population left untreated

High  
Prevalence

High  
Medical  
need

Pre-school  
aged children  
neglected

The current standard of care treatment cannot be readily administered to pre-school aged children and a correct dosing scheme has not been established

→ clear **unmet medical need** for a suitable pediatric medication for the **children aged 3 months to 6 years!**



# Pediatric Praziquantel Consortium: First International Public-Private partnership on schistosomiasis

- Established in July 2012 as the **first international, non-profit, public-private partnership in schistosomiasis**
- It operates through an innovative approach that engages new partners and collaborators as needed
- The model is built on a **solid governance** structure with:
  - a Consortium Board (led by Merck)
  - Development Team, Access Team & Subteams

Supported by international experts and funders, including the World Health Organization (observer).



**Consortium collaborators:** Merck (Germany); Astellas Pharma Inc. (Japan); the Swiss Tropical and Public Health Institute (Switzerland); Lygature (The Netherlands); Farmanguinhos (Brazil); the Schistosomiasis Control Initiative (SCI) Foundation (United Kingdom); Kenya Medical Research Institute (Kenya); Université Félix Houphouët-Boigny (Côte d'Ivoire); Klinikum rechts der Isar der Technischen Universität München (TUM) (Germany); Ministries of Health Côte d'Ivoire, Kenya and Uganda; African Institute for Health and Development (AIHD), Kenya; Makerere University, Uganda. The Consortium is financially supported by Merck; in-kind contributions from the Consortium's partners; and grants by the Global Health Innovative Technology (GHIT) Fund, and the European & Developing Countries Clinical Trials Partnership (EDCTP).

# Pediatric Praziquantel Consortium: Vision & Mission



Our **vision** is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children, including infants and toddlers.

Our **mission** is to develop, register and provide access to a suitable pediatric treatment for schistosomiasis in preschool-age children.





Thank you

[www.pediatricpraziquantelconsortium.org](http://www.pediatricpraziquantelconsortium.org)



# Disclaimer & Funding Statement

## Disclaimer

The content of this presentation reflects the views of the Pediatric Praziquantel Consortium.

## Funding statement

The Consortium is financially supported by Merck, in-kind contributions by partners and by grants from the Bill & Melinda Gates Foundation awarded in 2013, from the Global Health Innovative Technology (GHIT) Fund awarded in 2014, 2015, 2016, 2019 and 2020, and the European & Developing Countries Clinical Trials Partnership (EDCTP) in 2018 and 2021.



**EDCTP**

This project is part of the EDCTP2 programme supported by the European Union



Global Health Innovative Technology Fund

